40 related articles for article (PubMed ID: 19169687)
21. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
22. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.
Ho C; Sangha R; Beckett L; Tanaka M; Lau DH; Eisen DB; Burich RA; Luciw P; Khan I; Mack PC; Gandara DR; Davies AM
Invest New Drugs; 2011 Aug; 29(4):680-7. PubMed ID: 20148348
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
Doi T; Muro K; Yoshino T; Fuse N; Ura T; Takahari D; Feng HP; Shimamoto T; Noguchi K; Ohtsu A
Cancer Chemother Pharmacol; 2013 Sep; 72(3):643-52. PubMed ID: 23921573
[TBL] [Abstract][Full Text] [Related]
24. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Tahara M; Tamura T; Shirao K; Yamada Y; Otani S; Yang BB; Ohkura M; Ohtsu T
Int J Clin Oncol; 2009 Aug; 14(4):307-14. PubMed ID: 19705240
[TBL] [Abstract][Full Text] [Related]
25. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
[TBL] [Abstract][Full Text] [Related]
26. A rare but severe pulmonary side effect of cetuximab in two patients.
Achermann Y; Frauenfelder T; Obrist S; Zaugg K; Corti N; Günthard HF
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22843749
[TBL] [Abstract][Full Text] [Related]
27. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
29. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
Tabernero J; Pfeiffer P; Cervantes A
Oncologist; 2008 Feb; 13(2):113-9. PubMed ID: 18305055
[TBL] [Abstract][Full Text] [Related]
30. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
